Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cassandra A. Lickert"'
Autor:
Raymond L. Benza, Cassandra A. Lickert, Lin Xie, William Drake, Adesuwa Ogbomo, Huseyin Yuce, Michele R. Cole
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Limited evidence is available on outcomes associated with currently available medications from the endothelin receptor antagonist drug class (bosentan, ambrisentan, and macitentan) in elderly patients with pulmonary arterial hypertension. We evaluate
Externí odkaz:
https://doaj.org/article/02b0fd785af9437c86ccddb941e5808f
Autor:
Robert P. Frantz, Jerrold W. Hill, Cassandra A. Lickert, Rolin L. Wade, Michele R. Cole, Yuen Tsang, William Drake
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited. This retrospective database analysis evaluated
Externí odkaz:
https://doaj.org/article/41c21a40aa214abca64be48f966f6d14
Autor:
George Ruiz, Jason Yeaw, Cassandra A. Lickert, Ajita P. De, Rolin L. Wade, Janis Pruett, William Drake
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 5, Iss 2 (2018)
**Background:** Pulmonary arterial hypertension (PAH) is described by proliferation of small pulmonary arteries leading to increased pulmonary vascular resistance, right ventricular failure, and death. Research confirms long-term improvement in compo
Externí odkaz:
https://doaj.org/article/f29a74a9a3ed414e9a84b522a7ba133c
Autor:
Michele R. Cole, Adesuwa Ogbomo, William Drake, Cassandra A. Lickert, Lin Xie, Huseyin Yuce, Raymond L. Benza
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Limited evidence is available on outcomes associated with currently available medications from the endothelin receptor antagonist drug class (bosentan, ambrisentan, and macitentan) in elderly patients with pulmonary arterial hypertension. We evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac8bfb1557d619fef41adad73e80791d
https://doaj.org/article/02b0fd785af9437c86ccddb941e5808f
https://doaj.org/article/02b0fd785af9437c86ccddb941e5808f
Publikováno v:
The American journal of managed care. 21
Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially fatal cardiopulmonary syndrome that imposes a significant burden on patients in terms of morbidity and mortality, and on managed care organizations in terms of resource uti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f9f0416f560809b9381a15dc138a34a1
https://pubmed.ncbi.nlm.nih.gov/26168371
https://pubmed.ncbi.nlm.nih.gov/26168371